Drug intelligence / Profile preview

JY54

Development stage: Preclinical
Lead developer: Jiuyuan Gene Engineering
Modality: Peptides
Administration: Subcutaneous

Overview

JY54 is a peptide-based Class I new drug developed by Hangzhou Jiuyuan Gene Engineering Co. Ltd. for the treatment of obesity and overweight. As of late 2023 and early 2024, the drug was in the IND (Investigational New Drug) application stage. While the specific molecular target and mechanism of action for JY54 have not been publicly disclosed, it is part of a metabolic pipeline that includes other peptide therapeutics such as GLP-1 receptor agonists and dual amylin and calcitonin receptor agonists (DACRAs).

Targets

AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on JY54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY54.

Explore the full profile